Program
Anti-B7-H4 Antibody Drug Conjugate BG-C9074
Its studies are mostly in Carcinoma, Ovarian Epithelial, led by BeOne Medicines.
Furthest: phase 3, since Sep 3, 20262 company-led studies, 2 open or runningNext primary completion: Sep 28, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BeOne Medicines | 22 open or running | phase 3since Sep 3, 2026 | Jan 23, 2024 | Sep 28, 2027phase 1 · NCT06233942 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 23, 2024First study: phase 1 study in Advanced Solid TumorFirst studyNCT06233942 · 308 planned · United States, Australia, Brazil and more
- Sep 3, 2026Phase 3 study in Carcinoma, Ovarian EpithelialPhase 3 reachedNCT07811271 · 600 planned
Ahead
- Sep 28, 2027Primary completion: phase 1 study in Advanced Solid TumorNCT06233942
- Nov 30, 2029Primary completion: phase 3 study in Carcinoma, Ovarian EpithelialNCT07811271
TargetBeta
VTCN1 →read by rule
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the T-cell checkpoint ligand B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) ”NCIt, by rule
Other programs on VTCN1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| mocertatug rezetecan | GlaxoSmithKline | phase 3 | 11 |
| puxitatug samrotecan | AstraZeneca | phase 3 | 2 |
| Anti-B7-H4/Anti-4-1BB Bispecific Antibody ABL103rule | abl-bio-inc | phase 2 | 2 |
| Anti-B7-H4/MMAE ADC LNCB74rule | ligachem-biosciences-inc | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07811271Carcinoma, Ovarian Epithelial | 3 | Not yet recruiting | Nov 30, 2029 | 600 |
| NCT06233942Advanced Solid Tumor · United States, Australia, Brazil and more | 1 | Recruiting | Sep 28, 2027 | 308 |
How it is read
Names in the registry
- “BG-C9074”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Ovarian Epithelial, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.